Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medline Inc. - Class A common stock (NQ:MDLN)

35.50 +0.46 (+1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Medline Inc. - Class A common stock

News headline image
Medline (MDLN) Q2 2026 Earnings Call Transcript ↗
Sales hit $7.7 billion with 11.6% growth, but EBITDA guidance fell on cost pressures. 
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Medline Q2 Earnings Call Highlights ↗
Medline (NASDAQ:MDLN) reported second-quarter 2026 net sales growth of 12% to $7.7 billion, supported by demand across its medical-surgical product and supply-chain businesses, while raising its... 
Via MarketBeat
Topics Earnings Economy Initial Public Offering
Medline (NASDAQ:MDLN) Tumbles as Q2 Earnings Beat Offset by Lowered Full-Year EBITDA Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Why Symbotic Stock Dropped 24% in the First Half of 2026 And Is a Screaming Buy Now ↗
Ignore the noise. Symbotic's long-term story has only gotten stronger. 
Via The Motley Fool
Topics Supply Chain
Medline (NASDAQ:MDLN) Q1 Earnings: Revenue Beats, But Profits Slip on Tariff and Cost Pressures ↗
Via Chartmill
Medline Inc. (NASDAQ:MDLN) Reports Q4 Revenue Beat but EPS Miss Amid Margin Pressure ↗
Via Chartmill
News headline image
Why Symbotic Stock Slumped 21% in May And Just Hit a 2026 Low ↗
Is something seriously wrong with the automation expert, or is this a market overreaction and an opportunity to buy? 
Via The Motley Fool
Topics Economy
News headline image
Monashee Scales Back Its Bet on Structure Therapeutics ↗
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Symbotic Could Be a Massive Breakout Stock in 2026 After a 150% Surge in 2025 ↗
Symbotic's big growth moves of 2025 should propel the company to new highs. 
Via The Motley Fool
News headline image
How the Largest IPO of 2025 Could Be Healthy for Your Portfolio ↗
Medline is an appealing investment candidate – it has solid growth, operates in a steady industry, and a storied history. 
Via The Motley Fool
Topics Economy Initial Public Offering
News headline image
A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
Motley Fool Money: The Most Shocking Stories of 2025 ↗
Do you remember all of the surprises investors got in 2025? We had tariffs, AI upheaval, and even gold having a great year. 
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
News headline image
The 2025 IPO Market Review: A Year of Selective Recovery and the 2026 Outlook
As the final bell rings on 2025, the U.S. initial public offering (IPO) market has emerged from its multi-year hibernation, not with a frantic sprint, but with a calculated and selective stride. After... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Medline’s Blockbuster IPO Ignites Market Optimism: The Largest Debut Since 2021
In a stunning return to the public stage, Medline Industries (Nasdaq: MDLN) successfully executed the largest initial public offering (IPO) in the United States since 2021, pricing its shares at the... 
Via MarketMinute
Topics Economy Initial Public Offering World Trade
News headline image
Medline Industries (MDLN) Deep-Dive: The $54 Billion Return of a Healthcare Titan
The global healthcare landscape shifted decisively on December 16, 2025, with the public market return of Medline Industries (Nasdaq: MDLN). After four years under the stewardship of a private equity... 
Via PredictStreet
Topics Artificial Intelligence Earnings Economy
News headline image
Medline Stock Soars In Debut As Medical Supply Giant Seals 2025’s Biggest IPO ↗
The company's first day on the market underscored strong investor demand for scaled, profitable issuers as the U.S. IPO pipeline shows strength. 
Via Stocktwits
Topics Initial Public Offering Supply Chain
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.